Dismiss Notice
Links from our daily front page news are now being fed to this board. If you want to comment on any of the news articles, you can now do so there.


Discussion in 'AstraZeneca' started by Anonymous, Oct 13, 2011 at 9:34 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Any reason this new combo of Januvia and Zocor is not being discussed by BMS or AZ?
  2. Anonymous

    Anonymous Guest

    Because it will be about as successful as Caduet.
  3. Anonymous

    Anonymous Guest

    Merck reps I know calling this product

  4. Anonymous

    Anonymous Guest

    TAKE A CLOSE LOOK SNAPPERHEAD...NOT A BLOCKBUSTER BUT WILL FILL A NICHE...Not the same as caduet but will give some limited job security. Sales reps need something to sell! I don't see AZ launching anything earth shattering do you??
  5. Anonymous

    Anonymous Guest

    Well...you must not know about VIMOVO dude
  6. Anonymous

    Anonymous Guest

    Because it is the most idiotic launch of a product in recent memory. I can see it now at Merck:

    "What should we do that would be pretty awesome?"

    "Maybe we should grind up some of the Zocor tablets we were going to grind up to put in Vytorin, but since no one uses Vytorin anymore, let's grind up some Januvia tablets...mix em' up and create a product that no one will need.."

    "Jee whiz boss, that sounds great but there is a potential issue...that pesky dosage limitation that was added to the simvastatin label. Especially when you couple that with the fact that if a person has Type-2 diabetes they are immediately labeled as high to very-high risk. And since you need 80mg of simva to get most people to these goals...well that really won't fly."

    "No, no, let's just launch it anyway. I don't give a crap about that kind of stuff!"

    "Man boss you're swell, now I see how you got where you are in life!"

    "Damn right I'm smart, if my successful launch of Dulera didn't prove it this certainly will!"

    Need I go any further?
  7. Anonymous

    Anonymous Guest

    Januvia is a 3rd line diabetic agent (after met is maxed, after a TZD is ruled out). Zocor is the 3rd choice for a statin (after lipitor, after crestor). Liver panel sucks with Zocor.

    3rd line diabetic agent mixed with 3rd line statin= not worth your time to worry about. Knowing Merck- they priced this way out of the market and managed care will never cover it. They'll give away a bunch of this stuff with samples, vouchers and savings cards. Then, they'll shelve it in about a year.

    Remember- Merck reps are paid on customer service and district sales numbers... there is no reason for them to kill themselves to sell it. When you pay reps more on customer service surveys than on sales... They become professional caterers and "nice guys."
  8. Anonymous

    Anonymous Guest

    Although some of the posts here state the truth, this whole thread is based on wrong info. MCR reps that sell crestor & onglyza have already been sent a backgrounder & other training materials on juvisync. It is not being ignored
  9. Anonymous

    Anonymous Guest

    Just showing how stupid you people are by using CADUET as the reference point for a combination drug and saying it "stunk". Yeah it stunk for $500 million a year at its peak in 2007 and still "stinks" at $389 million in US sales for the 2010 year. Trust me, plenty of companies would love to have a stinky $389 million per year drug. Know what you are talking about before you open your piehole. Yes I used to be a pfizer rep, now I am AZ but I didnt check my brain in at the door.
  10. Anonymous

    Anonymous Guest

    Well ex prized rep, $389 mil in this company will get you a pink slip.